Light‐triggered dePEGylation with decreasing the diameter of hydroxyapatite nanocarriers for enhanced cellular uptake and tumor penetration

Abstract

PEGylation of nano-drug delivery systems (NDDSs) has been investigated to overcome the side effect of conventional chemotherapy including improving pharmacokinetics by prolonging drug circulation, reducing immune clearance and premature drug leakage. Although, PEGylation of NDDSs can also disturb the tumor penetration and cellular uptake with the diameter enhancement. Therefore, in this work, we constitute a light-triggered dePEGylation strategy, which results in the decrease of diameter of the pH-responsive hydroxyapatite drug nanocarriers (DOX@HAP-PEG) for enhanced cellular uptake and tumor penetration. Under light irradiation (650 nm), PEG chains can be availably separated from the nanocarrier by cleaving the Cy linker. Moreover, the cellular

Near-Infrared Fluorescent Hydroxyapatite Nanoparticles for Targeted Photothermal Cancer Therapy

“…Since the P800SO3 NIR fluorophore have a strong affinity for HAP, the simultaneous imaging and targeting capabilities of P800SO3-bound HAP (HAP800) could be further applied for effective photothermal cancer treatment. To enhance the tumor accumulation of HAP800, the non-covalent attachment of biocompatible and hydrophilic polyethylene glycol (PEG) on the surface of HAP800 can be considered for prolonging blood circulation and reducing immune clearance [ 31 , 32 ]. Hence, we hypothesized that HAP could assist the tumor-targeted delivery of P800SO3 via the enhanced permeability and retention (EPR) effect, as well as reduced reticuloendothelial system (RES) uptake, owing to noncovalent PEG coating.…”